glp1
Lixisenatide tracker
Educational reference for Lixisenatide. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
3 h
Tmax
2 h
Category
glp1
Also known as: Adlyxin, Lyxumia
Lixisenatide is an FDA-approved GLP-1 receptor agonist for type 2 diabetes. Subcutaneous injection.
Mechanism
A short-acting GLP-1 receptor agonist derived from exendin-4. It is associated with glucose-dependent insulin secretion and pronounced slowing of gastric emptying, with a relatively larger effect on post-meal glucose.
Research summary
Approved for type 2 diabetes and studied in the GetGoal program, with a cardiovascular outcomes trial (ELIXA). Marketed as Adlyxin/Lyxumia and also used in a fixed-ratio combination with insulin glargine.
Reported side effects
Gastrointestinal effects (nausea, vomiting, diarrhea) are most commonly reported. Prescribing information includes warnings such as pancreatitis. This is not a complete safety profile.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- GetGoal program and ELIXA cardiovascular outcomes trial · New England Journal of Medicine (2015)search PubMed for lixisenatide ELIXA
- Adlyxin / Lyxumia prescribing information · FDA prescribing information (2016)available via DailyMed / accessdata.fda.gov
TrackPep on seurantasovellus. Se tallentaa tekemäsi kirjaukset eikä koskaan suosittele tai laske määriä.